Syneos Health Schedules Second Quarter 2020 Earnings Call for Thursday, August 6, 2020

Rhea-AI Summary

Syneos Health (Nasdaq: SYNH) will announce its second quarter 2020 financial results on August 6, 2020, before an earnings call at 8:00 a.m. ET. The call can be accessed via webcast on the company's website or by telephone. Syneos Health, a fully integrated biopharmaceutical solutions organization, aims to enhance customer performance in over 110 countries, utilizing advanced technologies and insights to expedite crucial therapies to patients. A replay of the call will be available shortly after, along with audio access for a week.

Positive

• Syneos Health is positioned as a fully integrated biopharmaceutical solutions organization.
• The company operates in over 110 countries, indicating a global reach.

Negative

• None.

MORRISVILLE, N.C., July 01, 2020 (GLOBE NEWSWIRE) -- Syneos Health^® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its second quarter 2020 financial results on Thursday, August 6, 2020, prior to its earnings call at 8:00 a.m. ET. 

Participants may access the conference call live via webcast on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate via telephone, please dial +1 877 930 8058 within the United States or +1 253 336 7551 outside the United States, approximately 15 minutes prior to the scheduled start time. The conference ID for the call is 5227209.

A webcast replay will be available on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com after 1:00 p.m. on August 6. In addition, an audio replay will be available for one week following the call and will be accessible by dialing +1 855 859 2056 within the United States or +1 404 537 3406 outside the United States. The replay ID is 5227209.

About Syneos Health
Syneos Health^® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life^®, visit syneoshealth.com or subscribe to our podcast.

100%; border-collapse:collapse !important;">

50%; width:50%; min-width:50%;">Investor Relations Contact: Ronnie Speight Senior Vice President, Investor Relations +1 919 745 2745 investor.relations@syneoshealth.com

50%; width:50%; min-width:50%;">Press/Media Contact: Danielle DeForge Executive Director, External Communications +1 781 425 2624 danielle.deforge@syneoshealth.com

FAQ

When will Syneos Health release its Q2 2020 financial results?

Syneos Health will release its Q2 2020 financial results on August 6, 2020.

How can I access the earnings call for Syneos Health?

You can access the earnings call via webcast on the Syneos Health Investor Relations website or by dialing +1 877 930 8058 (U.S.) or +1 253 336 7551 (International).

What is the ticker symbol for Syneos Health?

The ticker symbol for Syneos Health is SYNH.

What is the purpose of Syneos Health?

Syneos Health is designed to accelerate customer performance in the biopharmaceutical sector, addressing modern market realities.